Advertisement

Topics

Latest "ProSolv CardioVascular" News Stories

15:58 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "ProSolv CardioVascular" found in our extensive news archives from over 250 global news sources.

More Information about ProSolv CardioVascular on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ProSolv CardioVascular for you to read. Along with our medical data and news we also list ProSolv CardioVascular Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProSolv CardioVascular Companies for you to search.

Showing "ProSolv CardioVascular" News Articles 1–25 of 2,700+

Relevant

Use of bivalirudin for anticoagulation in interventional cardiovascular procedures

(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0045 Zhen Ge, Jaya Chandrasekhar and Roxana Mehran from the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA consider the use of bivalirudin for anticoagu...


Obstructive sleep apnea and cardiovascular disease in women

(Cardiovascular Innovations and Applications) Obstructive Sleep Apnea and Cardiovascular Disease in WomenIn the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 421-434(14); DOI https://doi.org/10.15212/CVIA.2017.0064, Nimeh Najjar, MD, Peter Staiano, MD and Mariam Louis, MD f...

[Articles] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure.


Association between OSA and cardiovascular diseases in women

In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 421-434(14); DOI https://doi.org/10.15212/CVIA.2017.0064, Nimeh Najjar, MD, Peter Staiano, MD and Mariam Louis, MD from the University of Florida, Department of Medicine, Jacksonville, FL, USA consider obstructive sleep a...

Researchers reveal link between autoimmune and cardiovascular disease in mice

People with autoimmune diseases such as psoriasis, lupus and rheumatoid arthritis are at high risk of developing cardiovascular disease, even though none of these conditions seem to target the cardiovascular system directly.

Psychosocial stress, the unpredictability schema, and cardiovascular disease in women

(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 391-401(11); DOI: https://doi.org/10.15212/CVIA.2017.0065 Tomás Cabeza de Baca, PhD and Michelle A. Albert, MD, MPH from the Department of Medicine, University of California...

[Articles] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.

Albiglutide Beats Placebo for Cardiovascular Events in T2DM

THURSDAY, Oct. 4, 2018 -- For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online Oct. 2 in The Lancet to coincide with the annual meeting of...

Relationship between circadian misalignment and cardiovascular risk in women

In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 435-440(6); DOI: https://doi.org/10.15212/CVIA.2017.0070 Tracy Ashby, DO and Mariam Louis, MD, MSc, FCCP from the University of Florida, Department of Medicine, Jacksonville, FL, USA consider circadian misalignment and ca...

Air pollution may impact fetal cardiovascular system, Rutgers study says

(Rutgers University) Microscopic particles in air pollution inhaled by pregnant women may damage fetal cardiovascular development, according to a study by Rutgers researchers.The study, published in the journal Cardiovascular Toxicology, found that early in the first trimester and late in the third trimester were critical windows during which pollutants most affect the mother's and fetus' cardiova...

Aspirin use associated with reduction in cardiovascular events but increase in bleeding risk

1. In this systematic review and meta-analysis, while aspirin use among patients without cardiovascular disease was associated with fewer adverse cardiovascular events, it was not associated with a reduction in all-cause mortality. 2. The use of aspirin in patients without cardiovascular disease was associated with increased risk of major bleeding. Evidence Rating Level: 1 (Excellent) Study [R...

Personalised ultrasound scan showing atherosclerosis helps reduce cardiovascular risk

(The Lancet) Low adherence to medication and resistance to lifestyle changes have so far hampered prevention efforts for cardiovascular disease. Personalized scans and depiction showing biological age and plaque formation of arteries could help prevention of cardiovascular disease.

[Comment] HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

In 2017, GlaxoSmithKline announced its intention to withdraw the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons. This announcement came before the emergence of definitive evidence regarding the cardiovascular safety and efficacy of albiglutide. In The Lancet, Adrian Hernandez and colleagues1 report results from the Harmony Outcomes trial, which showed, in 9463 ...

EuroHeartCare 2019

(European Society of Cardiology) The event to attend for Cardiovascular Nurses and Allied Professionals.EuroHeartCare is the annual Congress of the Association of Cardiovascular Nursing and Allied Professions (ACNAP) aimed at helping support healthcare professionals deliver the best care possible to patients with cardiovascular disease.

Challenges in cardiovascular risk prediction and stratification in women

(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P. Velarde) pp. 329-348(20); DOI: https://doi.org/10.15212/CVIA.2017.0068 Sonia Henry, Rachel Bond, Stacey Rosen, Cindy Grines & Jennifer Mieres, from Hofstra School of Medicine, Manhasset, N...

[Comment] The Lancet Commission on women and cardiovascular disease: time for a shift in women's health

Cardiovascular disease is the leading cause of death in women worldwide. Ischaemic heart disease accounts for a third of all female deaths globally.1 Yet despite this massive burden and regional advocacy to raise awareness, cardiovascular disease in women is a silent killer. Although deaths from cardiovascular causes overall have decreased in the past three decades, women in many parts of the worl...

Announcing the TCT 2018 Press Conference Schedule

(Cardiovascular Research Foundation) The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and late-breaking clinical science that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will tak...

Top drivers behind cardiovascular market growth by 2024

Total sales for cardiovascular disease drugs will grow steadily over the next six years, from almost $47 billion in 2018...Read More... The post Top drivers behind cardiovascular market growth by 2024 appeared first on Pharmaceutical Technology.

Personalized ultrasound scan showing atherosclerosis helps reduce cardiovascular risk

Low adherence to medication and resistance to lifestyle changes have so far hampered prevention efforts for cardiovascular disease. Personalized scans and depiction showing biological age and plaque formation of arteries could help prevention of cardiovascular disease.

Psoriasis linked with need for cardiovascular interventions in patients with hypertension

(Wiley) Psoriasis is linked with increased risks of hypertension and cardiovascular disease, but its effect on the course of cardiovascular disease remains unknown.

Acute Cardiovascular Care 2019

(European Society of Cardiology) Acute Cardiovascular Care is the European meeting place for specialists dealing with patients in the acute setting. Learn, exchange and update your skills at the annual congress of the Acute Cardiovascular Care Association of the ESC.

Study finds albiglutide reduces cardiovascular events in patients with type 2 diabetes and existing cardiovascular disease

(Diabetologia) New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) and published in The Lancet shows that treatment with albiglutide (a type of drug called a glucagon-like peptide 1 receptor agonist) results in fewer cardiovascular events in people with type 2 diabetes and existing cardiovascular disease than treatment with placebo.

Bilirubin Improves Risk Prediction of Cardiovascular Death

Diabetes is one of the most prevalent disorders worldwide and cardiovascular (CV) disease is the leading cause of mortality and...

Getting leptin levels 'just right' may provide cardiovascular protection

(Medical College of Georgia at Augusta University) Like that famous bowl of porridge, when leptin levels are 'just right' they help protect our cardiovascular health, scientists say.This satiety hormone, made primarily by fat cells, is best known for telling our brains we are full. In obesity, leptin levels are high but the brain becomes resistant to its message and the cardiovascular system inste...

Omega-3 supplements do not protect against cardiovascular disease, meta-analysis shows

A meta-analysis of 79 trials showed that increasing long-chain omega-3 had little or no effect on death from all causes, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, stroke or arrhythmia.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks